中山大学附属肿瘤医院:ctDNA或可预测胃癌免疫治疗效果
创作:aluba 审核:aluba 2020年11月16日
  • 纳入46名接受PD-1单抗治疗的胃癌患者,对ctDNA进行NGS测序分析;
  • ctDNA中的最大体细胞突变等位基因频率(maxVAF)降低超过25%的患者,有着更长的中位PFS(7.3个月 vs. 3.6个月)及更高的应答率(53.5% vs. 13.3%);
  • 无法检测到ctDNA的患者的中位PFS为7.4个月,显著高于可检测到ctDNA的患者的4.9个月;
  • 基线ctDNA中的TGFBR2、RHOA及PREX2基因上存在特定突变的患者的中位PFS显著短于无突变患者。
主编推荐语
aluba
中山大学附属肿瘤医院的张东生团队与徐瑞华团队在Molecular Cancer上发表的一项最新研究,在46名接受PD-1单抗治疗的胃癌患者中发现,循环肿瘤DNA(ctDNA)的数量、突变频率及特定基因的突变状态可能影响患者的无进展生存期(PFS)及应答率,另外,ctDNA中特定基因的突变可能影响免疫相关不良事件发生率。
关键字
延伸阅读本研究的原文信息和链接出处,以及相关解读和评论文章。欢迎读者朋友们推荐!
图片
Molecular Cancer [IF:41.444]

The predicting role of circulating tumor DNA landscape in gastric cancer patients treated with immune checkpoint inhibitors

循环肿瘤DNA谱对接受免疫检查点抑制剂治疗的胃癌患者的预测作用

10.1186/s12943-020-01274-7

2020-10-30, Article

Abstract & Authors:展开

Abstract:收起
A more common and noninvasive predicting biomarker for programmed cell death 1 (PD-1) antibody remains to be explored. We assessed 46 patients with advanced gastric cancer who received PD-1 antibody immunotherapy and 425-genes next-generation sequencing (NGS) testing. Patients who had a > 25% decline in maximal somatic variant allelic frequency (maxVAF) had a longer progression free survival (PFS) and higher response rate than those who did not (7.3 months vs 3.6 months, p = 0.0011; 53.3% vs 13.3%, p = 0.06). The median PFS of patients with undetectable and detectable post-treatment circulating tumor DNA (ctDNA) was 7.4 months vs. 4.9 months (p = 0.025). Mutation status of TGFBR2, RHOA, and PREX2 in baseline ctDNA influenced the PFS of immunotherapy (p < 0.05). Patients with alterations in CEBPA, FGFR4, MET or KMT2B (p = 0.09) gene had greater likelihood of immune-related adverse events (irAEs). ctDNA can serve as a potential biomarker of the response to immunotherapy in advanced gastric cancers, and its potential role in predicting irAEs worth further exploration.

First Authors:
Ying Jin,Dong-Liang Chen,Feng Wang

Correspondence Authors:
Rui-Hua Xu,Dongsheng Zhang

All Authors:
Ying Jin,Dong-Liang Chen,Feng Wang,Chao-pin Yang,Xu-Xian Chen,Jin-qi You,Jin-Sheng Huang,Yang Shao,Dong-Qin Zhu,Yu-Ming Ouyang,Huiyan Luo,Zhiqiang Wang,Feng-Hua Wang,Yu-Hong Li,Rui-Hua Xu,Dongsheng Zhang

评论